Release Kinetics of Methylene Blue in Pluronic F-127 Hydrogel by Hayden, Meredith
University of Arkansas, Fayetteville
ScholarWorks@UARK
Animal Science Undergraduate Honors Theses Animal Science
8-2019
Release Kinetics of Methylene Blue in Pluronic
F-127 Hydrogel
Meredith Hayden
Follow this and additional works at: https://scholarworks.uark.edu/anscuht
Part of the Small or Companion Animal Medicine Commons, Veterinary Pathology and
Pathobiology Commons, Veterinary Preventive Medicine, Epidemiology, and Public Health
Commons, and the Veterinary Toxicology and Pharmacology Commons
This Thesis is brought to you for free and open access by the Animal Science at ScholarWorks@UARK. It has been accepted for inclusion in Animal
Science Undergraduate Honors Theses by an authorized administrator of ScholarWorks@UARK. For more information, please contact
ccmiddle@uark.edu.
Recommended Citation
Hayden, Meredith, "Release Kinetics of Methylene Blue in Pluronic F-127 Hydrogel" (2019). Animal Science Undergraduate Honors
Theses. 32.
https://scholarworks.uark.edu/anscuht/32


















    Meredith Hayden 
  Dale Bumpers College of Agricultural, Food and Life Sciences 
                                                         University of Arkansas 
Release Kinetics of Methylene Blue   2 
 
 




Materials and Methods………………………………………………………………………….…9 
Data Analysis………………………………………………………………………………….…11 
Discussion……………………………………………………………………………………......22 
















  “Between January 1998 and March 2000, veterinarians at the ASPCA National Animal 
Poison Control Center (NAPCC) consulted on more than 1,050 cases of accidental exposures to 
acetaminophen and 1,100 cases of ibuprofen ingestion in dogs and cats” (Richardson, 2000).  
NSAID toxicity has become an increasingly common occurrence in small companion 
animals within the last decade due to widespread usage (Zhou, Boudreau, & Freedman, 2014). 
Depending on the specific drug, treatment is centered around early decontamination and 
prevention of kidney and hepatic damage, and methemoglobanemia. Currently, 
methemoglobanemia is treated with intravenous delivery of methylene blue and less commonly 
through oral administration. While these methods have been shown to be successful, congenital 
forms of methemoglobinemia are more difficult to manage as reoccurring treatments are 
imperative.  
A biocompatible hydrogel composed of Pluronic F127 and methylene blue was created at 
various percent weight ratios to analyze release kinetics and determine the most effective 
composition for clinical treatment of methemoglobinemia. Using a hydrogel for localized 
delivery of methylene blue allows for long-term release of the drug, making treatment more 
feasible for affected patients and their owners.  
Initially, samples were created using 15-20 percent weight Pluronic F127 and deionized 
water in 20 mL vials. The polymer was allowed to dissolve by mechanical stirring using a 
magnetic stir bar for 24 hours. Once completely dissolved, 7.8%, 15.6%, or 31.2% methylene 
blue was added to each vial. Samples were placed in an oven at 37 degrees Celsius. Samples 
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were observed on 60-second intervals to check for gel formation. At this critical point, the 
solution was no longer viscous. Clinically favorable samples achieved a gel formation time at 
less than 10 minutes while other concentrations remained liquefied after the 24-hour period.  
A cumulative study was conducted with samples that did form a gel consistency to 
analyze the release kinetics of methylene blue. At day 0, 1 mL of phosphate buffered saline was 
added to each vial. Each day of the study, 1 mL of this phosphate buffered saline and methylene 
blue solution was removed and absorbance and concentration was measured using ultraviolet-
visible spectroscopy. This mixture was then be discarded and new phosphate buffered saline was 
added to each sample until the gel had completely degraded. Samples of Pluronic F127 at 19 
percent weight and above with 7.8% methylene blue proved to have the greatest longevity.  
A second trial was conducted using 19-21 percent weight Pluronic F127 with 7.8% 
methylene blue in 10 mL and 20 mL vials to compare the effects of surface degradation. In 
comparison to the 20 mL vial, the 10 mL vial showed significant increase in longevity. Increased 
concentrations of Pluronic F127  
Of the samples analyzed, 21 percent weight Pluronic F127 and 7.8% methylene blue 
proved to be the most clinically favorable sample for long-term delivery. Gel formation occurred 
instantly at room temperature and degraded over a period of 7 days. This specific sample also 
showed to have the highest percentage of methylene blue released during the cumulative release 








While the creation of hydrogels originated in 1894, they made their first appearance in 
the medical field in 1961, with the creation of soft contact lenses. They have consistently been a 
popular topic within the biomedical research community because of their biocompatible 
characteristics. Within the medical community today, they have commonly been used for wound 
therapy as they can mimic tissues and provide moisture to promote cell turnover (Wheeler, et al., 
1996). However, more recently they have also shown to be potential drug vehicles capable of 
providing localized delivery. As compared to oral or intravenous delivery, this treatment method 
is novel in its ability to decrease the likelihood of autoimmune responses (Milling, Zhang, & 
Irvine, 2017). 
Hydrogels are composed of a sophisticated hydrophilic matrix of polymers. Natural or 
synthetic polymers can be used in order to achieve an appropriate level of water absorption and 
longevity. These polymers are considered smart materials as they are capable of detecting and 
responding to changes in their physical and chemical environment (Ahmed, 2013). 
The objective of my research is to determine the most biocompatible composition of a 
hydrogel composed of Pluronic F127 and Methylene Blue. This will be determined by 
conducting a cumulative release study using ultraviolet-visible spectroscopy. I chose to analyze 
potential medical benefits of this localized drug delivery in veterinary medicine, specifically 








A 1% solution of methylene blue is typically administered intravenously to treat for 
methemoglobanemia in both humans and animals. Dosage for dogs and cats ranges from 1-
10mg/kg over the span of several minutes (Constable, Hinchcliff, Done, Grünberg, & Radostits, 
2017). Under normal circumstances, blood gas levels in small animals consists of 0-1% 
methemoglobin. Typically, oxidation of hemoglobin and reduction of methemoglobin occurs 
spontaneously each day to maintain homeostasis. However, methemoglobinemia can occur when 
the ferrous irons of the heme group in hemoglobin are oxidized from Fe2+ to Fe3+ and can no 
longer bind to oxygen molecules. An increase in as little as 10% of blood gas levels of 
methemoglobin can prevent oxygen from being released, leading to respiratory distress. At or 
above 20% methemoglobin levels are considered life threatening and patients can suffer from 
shock, seizures, and central cyanosis (Pharmocodynamics, n.d.). 
Methemoglobinemia is typically acquired in small animals through the ingestion of 
toxins, specifically NSAIDS such as acetaminophen. Because of the widespread usage of 
NSAIDS, toxicosis is common is small animals. Within dogs, acute toxicosis can occur after 
ingestion of 100 mg/kg of acetaminophen. However, patients may not display clinical signs until 
200 mg/kg is ingested. Cats can display clinical signs of cyanosis of mucous membranes at 10-40 
mg/kg. Methemoglobanemia can also be induced by the use of localized anesthetics such as 
lidocaine and benzocaine (Patton, Blamer, & Horak, 2016). 
  An autosomal-recessive form can occur in which enzymatic reduction of methemoglobin 
is depleted. Type I of this congenital form has been documented in dogs and results from a 
mutation in Cytochrome B5 Type A. Affected patients may display cyanosis, hypoxia, disturbed 
or absent pubertal development, and undermasculinization. Serum testing will display elevated 
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levels of methemoglobin and sex steroid deficiency, decreased levels of erythrocyte cytochrome 
b5, and normal levels of glucocorticoids and mineralocorticoids. Type II is characterized by a 
complete loss of enzymatic activity of cytochrome b5 reductase which eventually leads to 
encephalopathy, loss of motor skills, and decreased life expectancy. However, type II has not 
been documented in small animals (McKenna, et al., 2014).  
Methylene Blue is typically used for treatment in patients with either congenital or 
acquired forms of methemoglobinemia. It acts as a cofactor to reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) as it is reduced by NADPH to leukomethylene blue to in turn 
become an electron donor and non-enzymatically reduce methemoglobin to hemoglobin. 
Methylene Blue has the potential to increase the NADPH methemoglobin reductase pathway 
roughly 5-to-10 fold.  
However, when administered intravenously, methylene blue can lead to hemolytic 
anemia in patients with a glucose-6-phosphate dehydrogenase deficiency as it is an imperative 
enzyme in the formation of NADPH and low levels prevent function of the NADPH-dependent 
methemoglobin reductase pathway. Research of localized delivery of methylene blue in patients 
with G6PD deficiencies has not yet been conducted (Patton, Blamer, & Horak, 2016). The 
formation of Heinz bodies can be induced in cats when treated long-term with methylene blue 
containing antiseptics. However, when administered intravenously at reoccurring doses for 
nitrite-induced methemoglobinemia, there was no evidence to show that methylene blue caused 
Heinz body formation (Rumbeiha & Oehme, 1992). 
Pluronic F-127, a poloxamer, is composed of a hydrophobic polyoxypropylene chain and 
two chains of hydrophilic chains of polyoxyethylene. In aqueous solutions, it assembles into 
micelles that are dependent on polymer concentration and temperature. An important property of 
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Pluronic F127 is its ability to be thermoreversible. Below critical micelle temperature, the tri-
block of polymers becomes hydrated and soluble. This critical micelle temperature occurs near 
37 degrees Celsius, making it physiologically compatible. Above this critical temperature, it will 
form a gel consistency and begin degradation. Pluronic F127 has surfactant properties that allow 
it to interact with hydrophobic substances and biological membranes (Nie, Hsiao, Pan, & Yang, 
2011). In combination with water, it has been successfully used for drug and gene delivery as 
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Materials and Methods 
Aim 1: Fabrication and Characterization of the Injectable Hydrogel Platform.  
Rationale: To prepare the hydrogel, Pluronic F127 was added to deionized water in solutions of 
15-21 weight percent in 20 mL vials. The Pluronic F127 polymer was allowed to dissolve under 
mechanical stirring on a magnetic stir plate for 24 hours. Once this was complete, methylene blue 
was added in varying concentrations of 7.8, 15.6, and 31.2 weight percent to evaluate the release 
kinetics of different loading dosages. Each sample was then placed in an oven at 37 degrees 
Celsius. Gelation time was determined by the amount of time it took for the solution to no longer 
flow in the tube without reaching solidification.  
Aim 2: Evaluate Release Kinetics of Pluronic F127-Injectable Hydrogel System 
Rationale: Sample solutions were prepared as previously described with one caveat. Release 
studies were conducted by measuring absorbance spectroscopy of Methylene Blue. The 
absorbance curve generated by these trials were compared with a baseline absorbance curve from 
Methylene Blue solution. The most efficient absorbance indicated the concentration of Methylene 
Blue needed. Once this concentration was achieved, cumulative release studies were conducted to 
determine release time in 24-hour time intervals.  
Aim 3: Modification of Injectable Hydrogel and Re-evaluation of Release Kinetics Based on Vial 
Volume 
Rationale: Based on the results from previous methodology, a specific concentration of Pluronic 
F127 and methylene blue was chosen to evaluate the impact of vial volume on surface degradation 
and release kinetics. This was conducted by creating hydrogels as previously described within two 
different vial sizes of 10 mL and 20 mL. Concentrations of Pluronic F127 and methylene blue 
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were determined by longevity and absorbance values from original trials. Release studies were 






















Figure 1. 7.8% Methylene Blue in 20 mL Vial 
 
Gel formation did not occur for 5-15% weight Pluronic F127. Gel formation did occur at 
20% weight Pluronic F127 but an ice bath was needed to continue stirring the polymer as gel 
formation occurred immediately at room temperature. The ice bath decreased the temperature of 
the solution which allowed the magnetic stir bar to move freely. Complete degradation of the 





















5% No gel 
formation 
- - - - - - 
10% No gel 
formation 
- - - - - - 
15% No gel 
Formation 
- - - - - - 
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solution 










with 2 mL 
PBS 
0.38  
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Gel Time Day 1 
Absorbance 
Day 1 Concentration 
15% No gel formation - - 
16% No gel formation - - 
17% Gel formation after 
24 hours 
1.349 0.89 
0.5 mL hydrogel 
solution with 1.5 mL 
PBS added 
18% Gel formation after 4 
minutes 
1.007 0.66 
0.5 mL hydrogel 
solution with 1.5 mL 
PBS added 
 
Gel formation did not occur at 15% or 16% Pluronic F127. While gel formation did occur 
after 24 hours for 17%, this would not be a favorable gel time for clinical use. Both 17% and 
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15% No gel formation - - 
16% No gel formation - - 
17% Gel at 24 hours 1.341 
 
0.88 
0.5 mL hydrogel 
solution and 2.5 mL 
PBS added 
18% Gel at 7 minutes 1.359 0.5 mL hydrogel 
solution and 3 mL 
PBS added  
 
 Gel formation occurred at 17% and 18% Pluronic F127. 18% would be more clinically 
relevant because of the shorter gel time of 7 minutes. However, both concentrations completely 
degraded after one day.  
Higher concentration of 20 percent weight Pluronic F127 and 7.8% Methylene Blue 
showed slower release kinetics, so a new trial using 19, 20, and 21 percent weight Pluronic F127 
was conducted with 7.8% Methylene Blue. Two separate vial sizes of 10 mL and 20 mL were 
used to compare the impact of vial volume on surface degradation and release kinetics. For all 
samples, gel formation occurred instantly at room temperature. Samples with Pluronic F127 
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concentrations at or above 20 weight percent required an ice bath while stirring to prevent gel 
formation at room temperature. 
Figure 4. Calibrations Curve of Methylene Blue 
 
 
Figure 5. 19% Pluronic F127 and 7.8 % Methylene Blue in 20 mL Vial 
Day Absorbance Concentration 
1 1.000 0.66 
1 mL hydrogel solution and 2 
mL PBS added 
2 0.910 0.60 
1 mL hydrogel solution and 2 
mL PBS added 
                 
Figure 6. Cumulative Release of 7.8% Methylene Blue with 19% Pluronic F127 in 20 mL Vial 


















Calibration Curve of Methylene Blue 
Release Kinetics of Methylene Blue   15 
 
 
         
 
 
Figure 7. 20% Pluronic F127 and 7.8 % Methylene Blue in 20 mL Vial 
Day Absorbance Concentration 
1 0.798 0.53 
1 mL hydrogel solution and 4 
mL PBS added 
2 0.981 0.65 
1 mL hydrogel solution and 5 
mL PBS added 


























Cumulative Release of 7.8% Methylene Blue with 
19% Pluronic F127 in 20 mL Vial
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Figure 8. Cumulative Release of 7.8% Methylene Blue with 20% Pluronic F127 in 20 mL Vial 
     
 
Figure 9. 21% Pluronic F127 and 7.8 % Methylene Blue in 20 mL Vial 
Day Absorbance Concentration 
1 0.398 0.26 
1 mL hydrogel solution and 3 
mL PBS added 
2 0.810 0.53 
1 mL hydrogel solution and 3 

























Cumulative Release of 7.8% Methylene Blue 
with 20% Pluronic F127 in 20 mL Vial
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Figure 10. Cumulative Release of 7.8% Methylene Blue with 21% Pluronic F127 in 20 mL Vial                
 
 
Figure 11. 19% Pluronic F127 and 7.8% Methylene Blue in 10 mL Vial 
Day Absorbance Concentration 
1 0.971 0.64 
1 mL hydrogel solution with 
1 mL PBS added 
2 0.916 0.60 
1 mL hydrogel solution with 
2 mL PBS added 
3 0.752 0.50 
1 mL hydrogel solution with 
1 mL PBS added 























Cumulative Release of 7.8% Methylene Blue with 
21% Pluronic F127 in 20 mL Vial
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1 mL hydrogel solution with 
2 mL PBS added 
5 0.697 0.46 
1 mL hydrogel solution with 
2 mL PBS added 
6 0.933 0.62 
1 mL hydrogel solution with 
1 mL PBS added 
7 0.768 0.51 
1 mL hydrogel solution with 
2 mL PBS added 
 
 
Figure 12. Cumulative Release of 7.8% Methylene Blue with 19% Pluronic F127 in 10 mL Vial 
 


























Cumulative Release of 7.8% Methylene Blue 
with 19% Pluronic F127 in 10 mL Vial
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Figure 13. 20% Pluronic F127 and 7.8% Methylene Blue in 10 mL Vial  
Day Absorbance Concentration 
1 0.672 0.44 
1 mL of hydrogel solution with 2 mL PBS 
added 
2 0.957 0.63 
1 mL of hydrogel solution with 2 mL PBS 
added 
3 0.786 0.52 
1 mL of hydrogel solution with 2 mL PBS 
added 
4 0.838 0.55 
1 mL hydrogel solution with 1 mL PBS 
added 
5 0.960 0.63 
1 mL hydrogel solution with 1 mL PBS 
added 
6 0.505 0.33 
1 mL hydrogel solution with 2 mL PBS 
added 
 
Figure 14. Cumulative Release of 7.8% Methylene Blue with 20% Pluronic F127 in 10 mL Vial 
























Cumulative Release of 7.8% Methylene Blue 
with 20% Pluronic F127 in 10 mL Vial
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Figure 15. 21% Pluronic F127 with 7.8% Methylene Blue in 10 mL Vial 
Day Absorbance Concentration 
1 0.592 0.39 
1 mL hydrogel solution with 4 mL PBS 
added 
2 0.941 0.62 
1 mL hydrogel solution with 2 mL PBS 
added 
3 0.685 0.45 
1 mL hydrogel solution with 2 mL PBS 
added 
4 0.638 0.42  
1 mL hydrogel solution with 2 mL PBS 
added 
5 0.680 0.45 
1 mL hydrogel solution with 2 mL 
PBS added 
6 0.765 0.50 
1 mL hydrogel solution with 1 mL PBS 
added  
7 0.802 0.53 
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Cumulative Release of 7.8% Methylene Blue with 
21% Pluronic F127 in 10 mL Vial 




All three solutions within the large vials degraded within two days, making them more 
useful for short-term medical use. The 10 mL vials proved more relevant for long-term release as 
they degraded in the span of 6-7 days. 21% Pluronic F127 with 7.8% methylene blue in a 10 mL 
vial proved to be the most appropriate combination for long-term release as its degradation 
period was the longest and percentage of methylene blue released was the highest at 61.1%. For 
short-term use, 20% Pluronic F127 with 7.8% methylene blue in a 20 mLvial would be the most 
appropriate as it released the highest percentage of methylene blue at 52.8%. Degradation of the 
hydrogels was influenced by the volume of the vial in which they were created. Varying 
concentrations of methylene blue showed to be insignificant in altering surface degradation time 
and absorption. Manipulation of these variables was more influenced by vial size and polymer 
concentration. For long-term use as in the case of congenital patients, Pluronic F127 may not be 
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Conclusions and Implications 
Having a single injection of the methylene blue hydrogel would make treatment more 
feasible for patients requiring long-term treatment rather than maintaining a consistent intravenous 
method. Concentrations of both methylene blue and Pluronic F127 can be easily manipulated in 
order to achieve appropriate dosage and longevity for the specific patient. However, weight 
percentages of Pluronic F127 at 19%-21% would likely be a favorable concentration in a clinical 
setting as gel formation occurs instantly at body temperature. Localized delivery of methylene blue 
might also create potential for patients suffering from methemoglobanemia that also have a 
glucose-6-phosphate dehydrogenase deficiency as smaller amounts of NADPH might be efficient. 
Methylene blue hydrogels might also be more beneficial for cats as they’re more susceptible to 
Heinz body formation and hemolytic anemia. Delivering long-term, low doses could potentially 
reverse the effects of methemoglobinemia without inducing life-threatening side-effects.  
Moving forward, animal trials would be most appropriately conducted in large animals 
such as cattle and sheep as methylene blue is more commonly used for toxicosis. Future treatment 
in small animals may also be more financially effective as minimal amounts of Pluronic F127 and 
methylene blue are needed. Hospitalization and IV catheter placement would also no longer be 
necessary. Because of the thermoreversible properties of Pluronic F127, hydrogels could be 
prepared ahead of time and stored in a refrigerator at 3 degrees Celsius without gel formation or 
surface degradation. Upon being introduced into the body, the hydrogel solution would instantly 
form a gel consistency and begin release of methylene blue. 
Further analysis of different injection sites could also be conducted in the future to 
manipulate the rate of absorption of methylene blue. Because of its biocompatible nature, a 
hydrogel injectable isn’t isolated to subcutaneous delivery.  
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